07:52 EDT Lexeo Therapeutics (LXEO) up 31% at $8.50 after update on LX2006 accelerated approval
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics Advances FDA Discussions for LX2006
- Lexeo Therapeutics reports on LX2006 approval pathway
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Lexeo Therapeutics price target lowered to $15 from $20 at Chardan
- Lexeo Therapeutics, Inc.: Promising Gene Therapy Advancements and Strategic Positioning in Cardiac Treatments